Fig. 3 | Blood Cancer Journal

Fig. 3

From: ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children’s Oncology Group AAML0531 Trial

Fig. 3

a Comet Assay: percent tail DNA measured in HL60 cells transfected with ABCB1 expression constructs in response to calicheamicin treatment. Histograms represented fluoresce microscopy data were analyzed by Image J software to calculate average of tails per each group (***p < 0.001). b Calicheamicin reduced cell viability in HL-60 cells expressing ABCB1-1045642T as compared to ABCB1-WT as determined by AOPI. Dual-fluorescence viability, Acridine orange (AO) and propidium iodide (PI) (*p < 0.05)

Back to article page